Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment

Journal of Clinical Oncology

Volumn 18, Issue 17, 2000, Pages 3135-3143

  Davis, Thomas A ^a   Grillo López, Antonio J ^a   White, Christine A ^a   McLaughlin, Peter ^a   Czuczman, Myron S ^a   Link, Brian K ^a   Maloney, David G ^a   Weaver, Robin L ^a   Rosenberg, Jay ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; RETREATMENT; TREATMENT OUTCOME;

EID: 0033855660     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.17.3135     Document Type: Article

References (48)

1. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
2. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
3. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
4. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
5. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program
6. IDEC-C2B8 and CHOP chemoimmunotherapy of low-grade lymphoma
7. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
8. Combination immunotherapy of low grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) with rituximab and alpha interferon: Interim analysis
9. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
10. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines
11. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
12. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
13. Characterization of a human B lymphocyte-specific antigen
14. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
15. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
16. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas
17. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity
18. Primary CNS lymphoma
19. Efficacy controls and long-term follow-up of patients treated with rituximab for relapsed or refractory, low-grade or follicular NHL
20. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated or high-grade NHL
21. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
22. A clinical trial of anti-idiotype therapy for B cell malignancy
23. Monoclonal antibody-based therapies of leukemia and lymphoma
24. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
25. Generation of monoclonal antibodies for in vivo approaches
26. Response criteria and quality assurance of responses in the evaluation of new therapies for patients with low-grade lymphoma
27. Development of response criteria for low-grade or follicular lymphomas and application in a 166 patient study
28. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma
29. Survival after relapse of low-grade non-Hodgkin's lymphoma: Implications for marrow transplantation
30. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project
31. Applicability of the International Index for Aggressive Lymphomas to patients with low-grade lymphoma
32. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades
33. IDEC-C2B8 (rituximab): Clinical activity in clinically chemoresistant low-grade or follicular lymphoma patients and in patients relapsing after anthracycline therapy or ABMT
34. Prognostic factors for non-Hodgkin's lymphoma (NHL) PTS treated with chemotherapy (CRX) may not predict response duration in patients (PTS) treated with immunotherapy: Rituximab experience
35. Rituximab: Phase II (PII) retreatment (ReRx) study in patients (pts) with low-grade or follicular (LG/F) NHL
36. Retreatments with Rituxan (rituximab, IDEC-C2B8) have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL)
37. Follicular lymphoma: Prognostic factors for response and survival
38. Therapy of B cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
39. CD20-negative relapse in B-cell lymphoma after treatment with rituximab
40. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression
41. Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines
42. Chimeric anti-CD20 monoclonai antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: A Phase I/II clinical trial
43. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2
44. Rituximab: Correlation between effector cells and clinical activity in NHL